Treatment
Study treatment will be comprised of relacorilant, combined with nab-paclitaxel, and bevacizumab/
- Nab-paclitaxel: intravenous, day 1, 8, 15 of each 28-day cycle
- Bevacizumab: intravenous, day 1, 15 of each 28-day cycle
- Relacorilant: oral administration
Treatment duration
The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.
Eligibility
Main inclusion criteria:
- Histologic diagnosis of high-grade serous/endometrioid, epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Platinum-resistant disease (defined as progression <183 days from the last dose of platinum)
- At least 1 measurable (target) lesion per RECIST version 1.1
- 1 to 3 lines of prior systemic anticancer therapy for ovarian cancer
Main exclusion criteria:
- Has progressed while receiving weekly (every week or 3 out of 4 weeks) paclitaxel or nab-paclitaxel in the platinum-resistant ovarian cancer (PROC) setting
Disclaimer: This is an overview of the main in- and exclusion criteria which can also be found on clinicaltrials.gov (NCT06906341). Criteria might change during the course of the study due to amendments. Inclusion in the trial remains the responsibility of the principal investigator of the trial and will depend on patient eligibility and slot availability.
Contact
In case you feel your patient might be eligible for this trial or in case you want to have more information about this trial, please feel free to contact us via: lgog@uzleuven.be